Perrigo Company plc (PRGO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 28, 2025. Perrigo is a leading pure-play self-care company operating primarily in North America and Europe. The company is executing a "Three-S" strategy (Stabilize, Streamline, Strengthen) and managing significant restructuring initiatives, including "Project Energize" and "Supply Chain Reinvention."
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $1,056.3M | $1,065.5M | $2,100.2M | $2,147.5M |
| Gross Profit | $362.9M | $394.7M | $755.2M | $752.4M |
| Gross Margin | 34.4% | 37.0% | 36.0% | 35.0% |
| Operating Income | $45.4M | ($26.5M) | $92.3M | ($81.7M) |
| Net Income (Loss) | ($8.4M) | ($108.4M) | ($14.8M) | ($106.4M) |
| Diluted EPS | ($0.06) | ($0.79) | ($0.10) | ($0.78) |
| Cash & Equivalents | $454.2M | Balance Sheet Data | ||
| Total Debt (Long-term + Current) | $3,651.9M | Balance Sheet Data | ||
| Operating Cash Flow (YTD) | $11.4M | $8.1M | YTD Comparison |
Material Changes vs. Prior Period
- Profitability Improvement: Operating income improved significantly from a loss of $26.5M in Q2 2024 to a profit of $45.4M in Q2 2025. This was driven by a $103.7M reduction in operating expenses, primarily due to the absence of prior-year impairment charges ($34.1M) and lower restructuring costs.
- Revenue Decline: Net sales decreased 0.9% QoQ and 2.2% YTD, largely due to the divestiture of the HRA Pharma Rare Diseases and Hospital & Specialty businesses ($26.2M impact in Q2). Organic declines in Digestive Health and Oral Care were partially offset by growth in Nutrition (infant formula recovery) and Upper Respiratory categories.
- Restructuring: Restructuring charges were $8.7M in Q2 2025 compared to $36.9M in Q2 2024. Charges were primarily related to "Project Energize" and "Nutrition Network Optimization."
- Divestitures: The company completed the sale of the Richard Bittner Business in April 2025 for $14.4M, recording a pre-tax loss of $1.6M.
Guidance, Outlook, and Risks
- Strategic Initiatives: Management continues to execute "Project Energize," targeting $140M-$170M in annualized pre-tax savings by end of 2026, and the "Supply Chain Reinvention Program," targeting $200M-$300M in annual run-rate savings by 2028.
- Divestiture Pipeline: On July 13, 2025, the company entered an agreement to sell its Dermacosmetics branded business in Northern Europe, the Netherlands, and Poland for up to €327M. Closing is expected in Q1 2026.
- Tariff Risks: New U.S. tariffs are expected to increase global cost of goods sold by $10M-$20M in Q4 2025 and $50M-$60M on a full-year basis. The company plans to offset this via pricing and insourcing.
- Legal Contingencies: Significant litigation remains regarding price-fixing lawsuits related to the former Rx business (accrual of $30.0M) and securities litigation opt-out cases (accrual of $12.0M in Q2). The company also faces ongoing product liability suits regarding talcum powder and ranitidine, though many have been dismissed or settled.
- Infant Formula: The company continues to invest in remediation and quality enhancements following FDA warnings, with cash costs to date of approximately $22.6M.
Investor Verification Checklist
- Divestiture Closing: Verify the closing timeline and earn-out potential for the Dermacosmetics business sale to Kairos Bidco AB.
- Tariff Impact: Monitor Q3 and Q4 results for the realized impact of new U.S. tariffs on cost of goods sold and pricing strategies.
- Restructuring Progress: Track the execution of "Project Energize" and "Nutrition Network Optimization" against the stated savings targets and cash outflow schedules.
- Legal Reserves: Review updates on the price-fixing MDL bellwether cases and securities litigation opt-out settlements to assess potential changes to the $77.4M litigation accrual.
- Infant Formula Recovery: Assess the sustainability of the infant formula sales recovery and the impact of ongoing FDA regulatory requirements on margins.